SL PHARM Surges with China’s Innovation‑Drug Boom – A Lucrative Biotech Outlook
Explore how SL PHARM’s biotech focus aligns with China’s surging innovation‑drug boom—high P/E, 52‑week low entry point, and market‑wide momentum.
3 minutes to read
SL PHARM